

Q1 COCHRANE REVIEW

Systematic Review on Dietary Supplements in the Prevention and/or Treatment of Actinic Keratosis and Field Cancerization

A. Rodríguez-Luna^{a,b,1}, A. Zamarrón^{c,1}, C. Longo^{d,e}, G. Pellacani^f, K. Peris^{g,h}, P. Calzavara-Pintonⁱ, M.V. de Galvez^j, Y. Gilaberte^k, M. de Troya^l, Á. Juarranz^{b,c,*}, S. González^{m,*}

- ^a Faculty of Health Sciences, Universidad Loyola Andalucía, 41704 Dos Hermanas, Seville, Spain
- ^b Department of Experimental Dermatology and Skin Biology, Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Madrid, Spain
- ^c Department of Biology, Faculty of Sciences, Autonomía University of Madrid (UAM), Madrid, Spain
- ^d Department of Surgery, Medicine, Dental Medicine and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy
- ^e Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Skin Cancer Center, Reggio Emilia, Italy
- ^f Department of Dermatology, La Sapienza University, Rome, Italy
- ^g Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- ^h Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- ⁱ Department of Dermatology, University and ASST-Spedali Civili of Brescia, Italy
- ^j Photobiological Dermatology Laboratory Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain
- ^k Department of Dermatology, Miguel Servet University Hospital, IIS Aragón, Zaragoza, Spain
- ^l Dermatology Department, Costa del Sol University Hospital, Marbella, Spain
- ^m Department of Medicine and Medical Specialties, Alcalá de Henares University, Madrid, Spain

Received 7 October 2024; accepted 29 December 2024

KEYWORDS

Actinic keratoses;
Precancerous lesions;
Polyphenols;
Vitamins;

Abstract

Background: Actinic keratoses (AKs) are chronic, recurrent precancerous lesions primarily induced by long-term sun exposure, commonly found on sun-exposed areas such as the face, neck, hands, forearms, and lower legs. AKs are prevalent, affecting millions worldwide, and pose a significant risk of transforming into invasive squamous cell carcinomas (SCCs).

* Corresponding authors.

E-mail addresses: angeles.juarranz@uam.es (Á. Juarranz), salvagonrod@gmail.com (S. González).

¹ These authors equally contributed.

<https://doi.org/10.1016/j.ad.2024.12.019>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: A. Rodríguez-Luna, A. Zamarrón, C. Longo et al., Systematic Review on Dietary Supplements in the Prevention and/or Treatment of Actinic Keratosis and Field Cancerization, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2024.12.019>

Dietary supplements;
Skin cancer
prevention;
Photoprotection;
Systematic review

Objective: This systematic review aims to update the scientific evidence on the role of oral bioactives, nutraceuticals, or dietary supplements in the treatment of AKs and field cancerization, while evaluating their safety and efficacy profile.

Methods: A review plan was pre-registered in the PROSPERO database (CRD42023485985). Following the PRISMA guidelines, we identified, selected, and included relevant studies. We screened a total of 234 articles, thoroughly reviewed 38 full texts, and ultimately included 21 articles published from 2013 through 2023 for analysis.

Results: The selected studies were categorized into three groups based on the chemical nature of the supplements: polyphenols (11 studies), vitamins (8 studies), and others (2 studies). The studies included preclinical (9) and clinical (12) studies. Clinical trials have demonstrated the efficacy profile of polyphenolic supplements, such as *Polypodium leucotomos* extract (PLE) and others in improving skin health and reducing the risk of skin cancers. Preclinical studies highlighted the protective effects of polyphenols against UV-induced damage and neoplastic transformation. Vitamin supplementation studies revealed mixed results, with clear data showing benefits in reducing the risk of precancerous lesions and skin cancers after nicotinamide (NAM) treatment, while others did not demonstrate significant protective effects.

Conclusions: The review confirms the efficacy of polyphenols in preventing and treating AKs and related skin conditions. However, the role of vitamins and other supplements requires further investigation due to inconsistent and/or scarce findings. Future clinical trials should focus on diverse populations at higher risk of skin cancer and explore new ingredients as well as combinations of various ingredients to optimize therapeutic applications.

© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE
Queratosis actínica;
Lesiones
precancerosas;
Polifenoles;
Vitaminas;
Suplementos
dietéticos;
Prevención del
cáncer de piel;
Fotoprotección;
Revisión sistemática

Revisión sistemática sobre suplementos dietéticos en la prevención y/o tratamiento de la queratosis actínica y el campo de cancerización

Resumen

Antecedentes: Las queratosis actínicas (QA) son lesiones crónicas y recurrentes precancerosas, inducidas principalmente por la exposición solar prolongada, y que se encuentran comúnmente en áreas expuestas al sol, como la cara, el cuello, las manos, los antebrazos y las pantorrillas. Las QA son muy frecuentes, afectando a millones de personas en todo el mundo, y presentan un riesgo significativo de transformarse en carcinomas escamosos invasivos.

Objetivo: Esta revisión sistemática tiene como objetivo actualizar la evidencia científica sobre el papel de los bioactivos orales, nutraceuticos o suplementos dietéticos en el tratamiento de las QA y el campo de cancerización, evaluando su perfil de seguridad y eficacia.

Métodos: El plan de revisión fue registrado en la base de datos PROSPERO (CRD42023485985). Siguiendo las directrices PRISMA, identificamos, seleccionamos e incluimos estudios relevantes. Se examinaron 234 artículos, revisamos exhaustivamente 38 textos completos, y finalmente se incluyeron 21 artículos publicados entre 2013 y 2023 para su análisis.

Resultados: Los estudios seleccionados se clasificaron en 3 grupos según la naturaleza química de los suplementos: polifenoles (11 estudios), vitaminas (8 estudios) y otros (2 estudios). Los estudios incluyeron investigaciones preclínicas (9) y clínicas (12). Los ensayos clínicos han demostrado la eficacia de los suplementos polifenólicos, como el extracto de *Polypodium leucotomos* y otros, en la mejora de la salud de la piel y la reducción del riesgo de cánceres cutáneos. Los estudios preclínicos destacaron los efectos protectores de los polifenoles contra el daño inducido por los rayos UV y la transformación neoplásica. Los estudios de suplementación con vitaminas mostraron resultados mixtos, con datos claros que indican beneficios en la reducción del riesgo de lesiones precancerosas y cánceres de piel tras el tratamiento con nicotinamida, mientras que otros no demostraron efectos protectores significativos.

Conclusiones: La revisión confirma la eficacia de los polifenoles en la prevención y el tratamiento de las QA y afecciones relacionadas con la piel. Sin embargo, el papel de las vitaminas y otros suplementos requiere más investigación debido a hallazgos inconsistentes y/o escasos. Los futuros estudios clínicos deberían centrarse en poblaciones diversas con mayor riesgo de cáncer de piel y explorar nuevos ingredientes, así como combinaciones de varios ingredientes para optimizar las aplicaciones terapéuticas.

© 2025 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Actinic keratoses (AKs) are chronic and recurrent cutaneous lesions mainly induced by long-term exposure to sunlight. They are frequently located on sun-exposed areas of the body, such as face, neck, dorsum of the hands, forearms and lower legs. AKs arise as intraepithelial atypical proliferations of keratinocytes and are typically characterized by flat or slightly elevated lesions with a rough, scaly texture. According to recent estimates, 40 million Americans develop a new AK every year, a trend that is expected to grow in the coming years. Moreover, the appearance of AKs affect over one-third of adults older than 60s in Europe, and up to 60% in Australia.^{1–3} In Spain, the prevalence of AK is approximately 28.6% of individuals older than 45, with higher rates observed in men and older populations. This high prevalence underscores the significant burden AKs place on dermatology services in Spain.^{4,5}

The greatest risk associated with AKs lies in their potential to progress into invasive squamous cell carcinomas (SCC) through either a differentiated or undifferentiated pathway.⁶ In fact, AKs are defined as the initial forms of SCC, with a variable risk of malignant transformation estimated to be between 0.025 and 16% each year.^{7,8} Studies have demonstrated that the risk of developing SCC positively correlates with the number of AKs, since AKs are contiguous with an SCC in almost 97% of cases.⁸ Moreover, AKs and SCCs share certain genetic characteristics, such as mutations in the tumor suppressor gene p53 and *NOTCH*, among others.^{9,10}

On the other hand, the normal-appearing, sun-exposed skin surrounding AKs is also subject to cumulative actinic damage, with subclinical lesions, and therefore could present molecular alterations similar to those of AK lesions. In this regard, the concept of “field cancerization” was first introduced by Slaughter et al.¹¹ Currently, it describes the presence of precancerous and cancerous cells in a tissue close to a tumor and chronically exposed to a carcinogen.^{8,12} In the context of AK, field cancerization refers to the phenomenon where keratinocytes around a visible lesion look histologically normal but have genetic alterations identical to those in the lesion. These areas of skin with extensive UV damage are prone to develop greater numbers of AKs.¹³ Taking this into account, the presence of field cancerization requires a therapeutic strategy that should not only focus on treatment of clinically visible AKs as it is the case with lesion-targets therapies, such as cryotherapy, but also treat subclinical AKs to minimize their potential for transformation into SCC. Hence, field-directed treatments are highly recommended to address subclinical damage, reduce AK recurrence rates and potentially reduce the risk of SCC. Moreover, treatment options must allow treating large areas safeguarding patient’s comfort and achieving good cosmetic outcomes.^{12,14–16} Indeed, various field-directed modalities are approved for the treatment of sun-damaged areas with multiple AKs, including photodynamic therapy (PDT), and topical agents, such as 5-fluorouracil, imiquimod, tirbanibulin and diclofenac.^{17–20}

Consistent with this strategy, the combination of topical photoprotection and oral photoprotection is also a preventive option with potential as field-treatment for skin with severe actinic damage.²¹ Therefore, since natural

compounds obtained from plants or phytoconstituents are known to exert therapeutic effects mainly through their antioxidant, free-radical scavenging and anti-inflammatory properties, they can be considered to be included in field-targeted treatments along with standard pharmacological treatments. In this systematic review we aim to update the scientific evidence available on the role of oral bioactives or nutraceuticals or dietary supplements in the treatment of AKs and field cancerization, and evaluate the safety and efficacy profile reported by such treatments.

Methods

A review plan was pre-registered in the PROSPERO database (CRD42023485985). This article was developed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline, which covers identification, selection, eligibility, and inclusion.²²

Search strategy

We conducted a comprehensive literature search using various electronic databases, including but not limited to Pubmed, Google Scholar, EMBASE, The Cochrane Library, along with screening reference lists of eligible studies, and trials registers. Priority was given to Pubmed Central as the National Library of Medicine reference. Our search was limited to articles published from 2013 through 2023 (both years included), written in English, and relevant to our investigation on the effects of oral dietary supplements on skin health. Search criteria were adapted for each database used. The detailed retrieval technique is thoroughly outlined in [Supplementary Table S1 \(supplementary data\)](#).

Eligibility criteria

The research was included following the criteria below:

- Study type:** Clinical studies conducted among humans with AK diagnosed through clinical and dermoscopic evaluation, including assessment of the number, grade, and dermoscopic images. Clinical studies in patients with field cancerization (as diagnosed using AK numbers, AK size, Olsen clinical classification scheme, which grades AK lesions based on their thickness and degree of hyperkeratosis, among others). *In vitro* studies with skin cells or preclinical studies using artificial skin models. The primary exclusion criteria included (a) review studies; (b) *in vitro* studies developed with natural compounds that have no demonstrated clinical evidence on the skin. Subsequently, accepted papers needed to be peer-reviewed and have their complete text available.
- Participants/populations being studied:** Clinical studies involving adults aged ≥ 18 years were included. Primary exclusion criteria were (a) studies involving children and adolescents (younger than 18 years); (b) preclinical studies conducted on animals.
- Type of intervention:** A study was considered eligible if it assessed interventions for treating AKs, including individual lesion-based methods (e.g., cryotherapy) or field-targeted topical treatments (e.g., photodynamic

203 therapy, diclofenac, 5-fluorouracil, and imiquimod).
204 Additionally, cosmetic treatments could be used as an
205 adjuvant to these therapies. These interventions might
206 differ in safety, efficacy, and cosmetic results. Therefore,
207 oral therapies involving natural products, either alone
208 or in combination with the above-mentioned standard
209 pharmacological treatments could also be considered.

210 These parameters are indicated in Table 1 following
211 PICAR statement (Table 1).

212 Study selection

213 Two reviewers (A.R.-L. and A.Z.) independently screened
214 the documents for eligibility, initially examining titles and
215 abstracts using a Microsoft Excel document (Microsoft),
216 eliminating duplicates. Disagreements were resolved
217 through consensus, with the assistance of a third reviewer
218 (S.G.). Once inclusion criteria were met, the full texts
219 were imported into Mendeley (ELSEVIER LIMITED). After-
220 wards, these full texts were independently assessed by two
221 researchers (A.R.-L. and A.Z.) against the above-mentioned
222 criteria to determine their eligibility.

223 Data mining

224 We extracted data into a standardized extraction form using
225 an Excel Microsoft document (Microsoft). The characteris-
226 tics of each study are shown in Table 2, including research
227 specifics such as paper reference (lead author + year of
228 publication + study location); type of study (clinical or pre-
229 clinical trial); population and study characteristics; (sample
230 size, sex; age-years; health condition); natural product
231 intervention and control (content, daily dose); study dura-
232 tion; test conditions; outcome (measurement instruments
233 and parameters) and adverse effects.

234 Quality assessment

235 The risk of bias was evaluated using the standard risk
236 of bias assessment tool for randomized controlled trials
237 (RCTs) recommended by the Cochrane Collaboration, with
238 two reviewers independently conducting the examination.²³
239 This tool assesses seven types of bias: selection bias (ran-
240 dom sequence generation and allocation concealment),
241 performance bias (blinding of participants and researchers),
242 detection bias (blinding of outcome assessors), attrition bias
243 (incomplete outcome data), reporting bias (selective report-
244 ing), and other biases (such as changes in lifestyle during the
245 study, unstable testing conditions, and potential conflicts of
246 interest). Each study was rated for these criteria as hav-
247 ing a “low,” “high,” or “unclear” risk of bias. A criterion
248 was considered as low risk if the study adequately reported
249 methods to prevent bias according to Cochrane guidelines.
250 High risk was allocated if the methods described could not
251 eliminate bias, and unclear risk was used when information
252 was insufficient, irrelevant, or missing.²⁴

Results

Study characteristics

255 Following the screening of titles and abstracts of 234 arti-
256 cles and a thorough review of the full text of 38 articles, 21
257 articles published from 2013 through 2023 were ultimately
258 chosen for our analysis (see Fig. 1). The studies were cate-
259 gorized based on the chemical nature of the agent chosen
260 for dietary supplementation. Therefore, we selected three
261 categories: administration of polyphenols (11 studies), vita-
262 mins and oligoelements (8 studies), and a third category
263 called “others”, which includes various types of ingredi-
264 ents (2 studies). Type of study included preclinical (9), and
265 clinical (12) studies (Fig. 1 and Table 2).

Patients’ characteristics

267 Overall, our review analysis included 10,463 patients, with
268 a mean age of 52.4 years (range, 21–91 years). Based on the
269 articles that provided this information, we determined that
270 51.8% ($n = 5426$ women out of 10,493) of participants were
271 women.

Risk of bias in research studies

273 The examination of each aspect of bias within the selected
274 research was represented as percentages in Fig. 2, based
275 on the researchers’ evaluation. Most trials showed strengths
276 in their design and methods. Consequently, the risk of bias
277 was low in most parameters analyzed: 91.7% of randomized
278 controlled trials (RCTs) adequately mentioned randomiza-
279 tion, with only one study being considered high risk (8.3%).
280 Blinding of both subjects and researchers was implemented
281 in 8 out of 12 studies (66.7%) and blinding of evaluators
282 when analyzing results was also implemented in 8 out of
283 12 studies (66.7%). Regarding the aspect of attrition biases,
284 most studies (8/12, 66.7%) exhibit a high risk, as many
285 of them experienced drop out of several study subjects,
286 mainly due to non-compliance with the oral supplement
287 intake. In all selected studies, reporting bias posed a low
288 risk, as most (11,712, 91.7%) studies provided precise data
289 and none of them showed a lack of information, a crucial
290 factor for ensuring transparency and reliability in clinical
291 research. Four studies (33.3%) were rated at high risk for
292 “other biases,” due to potential conflicts of interest and
293 insufficient details regarding compliance with supplement
294 consumption and maintenance of lifestyle habits.

Data extracted: results and discussion

Supplementation with polyphenols

296 Eleven studies reported on the administration of polypheno-
297 lic compounds for the treatment of AKs, BCC and SCC and
298 actinic ageing, as well as prevention of UVB-induced dam-
299 age to the skin (CPDs formation, erythema, etc.). Five out
300 of the 11 were clinical trials and 6 were preclinical studies.

301 Regarding clinical trials, *Polypodium leucotomos* extract
302 (PLE), polyphenols from black tea, and a combination of
303 rosemary and grapefruit polyphenols were administered as
304

Q5 Table 1 Eligibility criteria pertaining to the population and clinical areas, interventions, comparators, attributes of CPGs and recommendation characteristics (PICAR) statement.

PICAR element	Study specific criteria
Population & clinical area(s)	<ul style="list-style-type: none"> - Adults (aged 18 and above) diagnosed with actinic keratosis - Preclinical studies: <i>In vitro</i> studies with skin cells or preclinical studies in skin models.
Interventions	<ul style="list-style-type: none"> - Compounds of natural origin that have clinical evidence in the prevention of field cancerization and actinic keratosis.
Comparators	No comparator applicable.
Attributes of eligible studies	<ul style="list-style-type: none"> - <i>Language</i>: English - <i>Publication years</i>: 2013–2023 - <i>Type of publication</i>: Clinical and preclinical studies. Published papers must be peer-reviewed articles with full text. - <i>Publishing region</i>: All - <i>Clinical scope</i>: Studies that evaluate oral compounds with established clinical evidence and focus on the pathways involved in the development of actinic keratosis or field cancerization. - <i>Format</i>: Clinical trial and <i>in vitro</i> study - <i>Purpose</i>: Reducing actinic keratosis and field cancerization - <i>Interventions</i>: individual lesion-based (e.g., cryotherapy) or field-directed topical treatments (e.g., diclofenac, 5-fluorouracil, imiquimod). Additionally, cosmetic treatment could be used as adjuvant therapy of these treatments. These might vary in terms of safety, efficacy, and cosmetic outcomes. Therefore, only oral therapies with natural products will be considered, also alone or in combination with cited standard pharmacological treatments.
Recommendation characteristics	<ul style="list-style-type: none"> - <i>Scope</i>: natural compounds that have demonstrated oral clinical efficacy in improving skin conditions by clinical evidence or modulation on the pathways involved in the development of actinic keratosis or field cancerization. - <i>Duration of treatment</i>: non-applicable. - <i>Levels of confidence</i>: non-applicable. - <i>Comparators</i>: In clinical studies a placebo (a group of patients who will not be exposed to the natural product treatment) must be included. - <i>In vitro models</i>: A control which will not be exposed to the natural product treatment. - <i>Locating recommendations</i>: non-applicable.

305 dietary supplements for the prevention of AKs, UV-induced
 306 erythema and lipid peroxidation, the improvement of signs
 307 of photoaging, and the reduction of incidence of BCCs
 308 and SCCs. Overall, these studies included a total of 1595
 309 patients, with a mean age of 51.7 years, ranging from 28 to
 310 85 years. Data showed that 54.4% ($n = 867$ women/1595) of
 311 participants were women.

312 Preclinical experimentation included the evaluation of
 313 PLE, flavonols (quercetin, kaempferol and galangin), and
 314 extracts obtained from the leaves of *Hamamelis virginiana*
 315 and lotus to prevent genomic UV-induced damage and for-
 316 mation of CPDs, to inhibit actinic aging and progression of
 317 AKs and to suppress neoplastic transformation.

318 Research snippets

319 *Polypodium leucotomos* extract (PLE)

320 A recent clinical trial analyzed the effect of PLE, orally
 321 administered in combination with topical sun protection
 322 SPF100, in subjects with severe photoaging and history of
 323 at least three AKs. The combination of topical and oral PLE
 324 at a daily dose of 240 mg led to an improvement in AKASI
 325 and AK-FAS parameters and reduced the number of new AKs

326 and the need for additional intervention to a greater degree
 327 than in the case of topical treatment alone.²¹ Thus, combi-
 328 nation of topical and oral photoprotection with PLE can help
 329 prevent the onset of further lesions in sun-exposed areas of
 330 the skin.²¹

331 Additionally, this extract has not only demonstrated the
 332 effectiveness of skin cancer prevention but also skin cancer
 333 treatment. A clinical trial assessed whether PLE could
 334 improve the effectiveness of PDT in decreasing the recur-
 335 rence of AKs.²⁵ For this purpose, patients with at least two
 336 visible AKs on the scalp were categorized into two groups:
 337 one receiving two sessions of MAL-PDT alone, and the other
 338 receiving the same two PDT sessions along with oral PLE sup-
 339 plementation (daily doses of 480 mg, starting 1-week after
 340 last session) for 6 months. Clinical, dermoscopic, and fluo-
 341 rescent image data showed that at the 6-month follow-up,
 342 PDT plus oral PLE resulted in a higher clearance rate than
 343 PDT alone. Thus, PLE supplementation appears to enhance
 344 long-term PDT effectiveness, significantly reducing the num-
 345 ber of AKs.²⁵

346 A recent study performed by Gandarillas et al. using
 347 primary human epidermal keratinocytes suggests that PLE
 348 has the capacity to induce the repair of genomic damage

Table 2 Characteristics and research specifics of each included study: paper reference (lead author + year of publication + study location); type of study (clinical or preclinical trial); population and study characteristics; (sample size, sex; age-years; health condition); natural product intervention and control (content, daily dose); study duration; test conditions; outcome (measurement instruments and parameters) and adverse events.

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years					Health condition	Contents, daily dose		Contents, daily dose
<i>Polyphenols</i>											
Auremma, 2015, Italy ²⁵	Clinical trial	n = 34 100% F	67–84	≥2 visible AKs on the scalp. Hamilton–Norwood baldness scale ≥IV	2 sessions of MAL-PDT one week apart + oral PLE supplementation (960 mg/day for 1 month and then 480 mg/day for 5 months)	2 sessions of MAL-PDT without subsequent PLE supplementation	25 w	Clearance rate	- Clinical, dermoscopic, and fluorescent images (FotoFinder Dermoscope and Medicam 800HD) - AK count	Scalp	No
Miura, 2015, Australia ²⁹	Clinical trial	n = 1325 44% M	35–48	Follow-up of all patients to evaluate association between black tea consumption-new BCC/SCC	Black tea consumers. Information about consumption: questionnaires 1992, 1994 and 1996.	Never drinking black tea	10 y (follow-up)	Relative risks (RRs) + 95% confidence (BCC/SCC incidence)	- Questionnaires - Diagnosed BCCs and SCCs count	Full-body skin examination	No

Table 2 (Continued)

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years					Health condition	Contents, daily dose		Contents, daily dose
Pérez-Sánchez, 2014, Spain ³⁰	Clinical + preclinical trial	n = 10 90% F	28-52	- <i>Clinical trial</i> : healthy human volunteers - <i>In vitro study</i> : human keratinocytes (HaCaT)	Nutroxsun®: citrus extract enriched in citrus bioflavonoids (22.57 ± 2.65 GAE/100 g dw) + rosemary extract containing phenolic compounds and diterpenes (57.16 ± 1.25 GAE/100 g dw) - <i>Clinical trial</i> : Nutroxsun® intake (capsule 250 mg daily) - <i>In vitro study</i> : UVB irradiation (800 or 1200 J/m ² dose) in the presence of the extracts (citrus extract alone, rosemary extract alone or Nutroxsun®)	- <i>Clinical trial</i> : Each subject was used as his or her own control. - <i>In vitro study</i> : UVB irradiation (800 or 1200 J/m ² dose) in the absence of extracts.	24 w	<i>Clinical trial</i> : MED (after 29, 57 and 85 consecutive days of ingestion of Nutroxsun®) <i>In vitro study</i> : - MTT (cell viability) - H2DCFDA (ROS generation) - Comet assay (DNA damage)	UVB lamp Bio-Link Crosslinker BLX-E312 Mexameter® (colorimetric measurements)	-	NR

Table 2 (Continued)

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years					Health condition	Contents, daily dose		Contents, daily dose
Nobile, 2016, Spain ³¹	Clinical trial	n = 95	30–55	Healthy adults with mild-to-moderate chrono- or photoageing clinical signs and skin phototype I–III	<i>Nutroxsun</i> [®] : obtained from dried rosemary (<i>Rosmarinus officinalis</i>) and grapefruit (<i>Citrus paradisi</i>). Total phenolic standard content >35 GAE/100 g dw. <i>Short-term test</i> : Dose of <i>Nutroxsun</i> [™] (100 or 250 mg) 15 min before UVB exposure (1 MED) + 2 doses of <i>Nutroxsun</i> [™] (24 and 48 h after irradiation, respectively) <i>Long-term test</i> : 100 or 250 mg <i>Nutroxsun</i> [®] once daily for 2 months. UVB exposure series.	Placebo intake (mal-todextrin)	8 w	Measurement of: - MED - Skin redness - Skin LPO - Wrinkle depth - Skin elasticity	- Multiport 601-300 W Solar simulator - Spectrophotometer/colorimeter CM-700D - 3-D microtopography imaging system (PRIMOS 3D lite) - Skin viscoelasticity analyser (Cutometer MPA 580)	Specific sites on skin of the back	No

Table 2 (Continued)

Study location	Study population				Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects
	Type of study	Sample size, sex	Age, years	Health condition					Contents, daily dose	Contents, daily dose	
Pellacani, 2023, Italy ²¹	Clinical trial	n = 131 84% M	60–85	≥3 AKs on face or scalp. Photoaging score >16	Topical photoprotection (SPF100 twice daily) + oral photoprotection (PLE oral, 240 mg/day)	Non-specific photoprotection measures	48 w	- AKASI and AK-FAS scores - New AKs - RCM evaluation	- Direct inspection - Lesion count - Vivastack	Scalp, forehead and face	No
Maini, 2015, Canada ³²	Preclinical trial	-	-	EpiDerm™: artificial skin mimic	EpiDerm™ samples were treated topically with: - 50 µL and 100 µL of 26 µM quercetin (1 nmol, 2 nmol respectively) in acetone. - 300 µL of 52 µM (15 nmol) flavonol (quercetin, kaempferol, galangin) in acetone for a final concentration of 4 nmol/cm ² . EpiDerm™ samples were exposed to UVB/UVA	Dark control	-	- HPLC/APCI MS/MS method (for CPDs analysis) - ELISA (for MMP-1 and TNF-α secretion)	- FS20T12/UVB lamp - F20T12/BL/HO UVA lamp - UVP UVX-31/36 sensors	-	-

Table 2 (Continued)

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years Health condition					Contents, daily dose	Contents, daily dose		Measurement instrument
Torricelli, 2017, Italy ²⁷	Preclinical trial	-	-	Reconstructed human epidermis (RHE) (Episkin) samples	PL leaves extract topically applied on RHE at 0.5 mg/mL and exposed to 300 mJ/cm ² UVB	- RHE irradiated without PL (positive control) - RHE non-irradiated (negative control)	-	- Histology - p53, p21, and Ki67 expression - CPDs detection - EGF production	UVB lamp	-	-
Pain, 2018, Canada ³³	Preclinical trial	-	-	- Fibroblasts from a 63-year-old healthy woman - Biopsies of abdominal skin from a 27-year-old woman	Fibroblasts: - <i>Treatment 1.</i> UVA irradiation: 7.5 J/cm ² + incubation with <i>Hamamelis virginiana</i> extract for 16 h - <i>Treatment 2.</i> Incubation with <i>Hamamelis virginiana</i> for 24 h + UVA irradiation: 7.5 J/cm ² + incubation with <i>Hamamelis virginiana</i> extract for 16 h Biopsies: - UVA (5 J/cm ²) + 0.5% systemic <i>Hamamelis virginiana</i> extract	Fibroblasts: - UVA-exposed fibroblasts (7.5 J/cm ²) Biopsies: - Dark control - UVA-exposed biopsies (5 J/cm ²)	-	- Evaluation of LOXL1 expression - Evaluation of elafin expression	- q-RT-PCR - Immunohistochemistry: staining quantification	-	No

Table 2 (Continued)

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years					Health condition	Contents, daily dose		Contents, daily dose
Portillo-Esnaola, 2021, Spain ²⁸	Preclinical trial	-	-	B16-F10 mouse melanocyte cell line	Cells were treated with 0.3 and 0.75 mg/mL of Fernblock® and exposed to UVA light (94, 282, 470 and 658 mJ/cm ²)	- Cells without FB treatment and non-irradiated - Cells treated with FB but non-irradiated - Cells non treated with FB but exposed to UVA	-	- Cell viability assay - Dark-CPD formation - NO•, O ₂ ⁻ and ONOO ⁻ formation	- CAMAG UV lamp	-	-
Gandarillas, 2023, Spain ²⁶	Preclinical trial	-	-	Primary human keratinocytes isolated from neonatal foreskins	Keratinocytes were treated with Fernblock® (hydrophilic extract from <i>P. leucotomos</i>) 0.8–2.4 mg/mL and exposed to 25 mJ/cm ² UVB	- Keratinocytes untreated. - Keratinocytes only exposed to UVB.	-	- Clonogenicity assay - Cell cycle analysis - DNA analysis (comet assay) - Involucrin and p53 expression	- UPV CL-1000 Series UV crosslinker - CytoFLEX cytometer	-	-

Table 2 (Continued)

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years					Health condition	Contents, daily dose		Contents, daily dose
Tung, 2023, Taiwan ³⁴	Preclinical trial	-	-	Murine skin JB6 P+ cells	Lotus leaves extracts: - <i>Water extracts (LL-WE)</i> : 6.25, 12.5, 25, and 50 mg/mL - <i>Ethanol extracts (LL-EE)</i> : 3.125, 6.25, 12.5, 25, and 50 mg/mL - <i>LL-WE further extracted with ethanol (LL-WREE)</i> : 3.125, 6.25, 12.5, 25, and 50 mg/mL JB6 P+ cells were treated with TPA (to induce cell transformation) and incubated with different lotus leaves extracts	Untreated murine JB6 P+ cells	-	- Cell viability and growth - ARE-luciferase activity - Nrf2, HO-1, NQO1 and UGT1A1 expression	- Beckman microplate spectrophotometer - Beckman luminometer - PCR detection system	-	-
Vitamins Chen, 2015, Australia ³⁵	Clinical trial	n = 386 63% M	30–91	Patients with ≥ 2 keratinocyte cancers in last 5 years	<i>Nicotinamide (vit B3) group</i> : 500 mg, twice daily (coated tablets)	Placebo: placebo coated tables twice daily	48 w	- New NMSC - New SCC/BCC/AK	- Dermatologist skin check - Lesion count	Face, head and neck, trunk	AE (similar in both groups)

Table 2 (Continued)

Study location	Study population				Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects
	Type of study	Sample size, sex	Age, years	Health condition	Contents, daily dose	Contents, daily dose			Measurement instrument	Parameter (measuring sites)	
Donnenfeld, 2015, France ³⁹	Clinical trial	n = 5880 42% M	43–56	Participants from Vitamines et Minneraux Antioxydants (SU.VI.MAX) study	Active group: dietary folate	-	8 y	Melanoma and NMSC	- Dietary records from participants (foods and beverages) - Count of diagnosed skin cancers (melanoma, NMSC)	Full body	NR
Freitas, 2015, Brazil ⁴⁰	Clinical trial	n = 84 31% M	45–77	Patients with a history of NMSC previously treated by surgery	Supplemented group: daily antioxidant complex capsule (500 mg vit C, 400 IU vit D and 50 mg zinc)	Placebo group: daily lactose capsule	8 w	NMSC oxidative biomarkers: - 15-F2t-isoprostane - Thiobarbituric acid reactive substances (TBARS) - Nitrite - Total antioxidant capacity (TAC)	Oxidative markers: measurement in plasma	Plasma	NR

Table 2 (Continued)

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years					Health condition	Contents, daily dose		Contents, daily dose
Chen, 2016, Australia ³⁶	Clinical trial	n = 22 77.3% M	42–81	- Immunosuppressed renal transplant recipients	Nicotinamide (vit B3) group: 500 mg, twice daily (coated tablets).	Placebo: placebo coated tables twice daily	24 w	- New NMSC - New SCC/BCC/AK	- Dermatologist skin check - Lesion count	Face, scalp, forearms and hands	AE
Passarelli, 2020, USA ⁴²	Clinical trial	n = 2259 63% M	45–75	Patients who underwent polypectomy for ≥ 1 colorectal adenoma in last 120 d	- Vitamin D3 group: 1000 IU/d of vitamin D3 - Calcium group: 1200 mg/d of calcium - Vitamin D3 + calcium group: 1000 IU/d of vitamin D3 + 1200 mg/d of calcium.	Placebo supplementation	3 or 5 y	New keratinocyte cancers (BCC and SCC)	- Dermatologist skin check - Lesion count	Full body	NR
Allen, 2023, Australia ³⁷	Clinical trial	n = 158 59% M	49–74	- Solid-organ transplant recipients with ≥ 2 keratinocyte cancers in last 5 years	Nicotinamide (vit B3) group: 500 mg, twice daily (coated tablets)	Placebo: placebo coated tables twice daily	48 w	- New keratinocyte cancer - New SCC	- Dermatologist skin check - Lesion count	Face, head and neck, trunk	AE (similar in both groups)

Table 2 (Continued)

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years					Health condition	Contents, daily dose		Contents, daily dose
Lin, 2014, China ⁴¹	Preclinical trial	-	-	- Human epidermoid carcinoma A431 cells - p16-knockout fibroblasts - p21-knockout fibroblasts	Cells were exposed to 30 J/m ² UV light and treated with either various concentration of vitamin C (10–200 ug/mL)	- Normal human epidermal keratinocytes (NHEK)	-	- Apoptosis (expression of p12, p21, and Tet1/2/3 genes) - q-RT-PCR - DNA methylation (MethylFlash Methylated DNA Quantification)	- Solar simulator (SUV100)	-	-
Camillo, 2022, Italy ³⁸	Preclinical trial	n = 30 74% M (skin biopsies' donors)	46–91	Field cancerization human primary keratinocytes (FC-HPKs) isolated from patients with signs and personal history of intrinsic skin aging, affected by precancerous skin lesions, dysplastic nevi, NMSCs, and/or cutaneous melanoma.	FC-HPKs were treated with nicotinamide (NAM) (5, 25, and 50 mM) for 18, 24 and 48 h. Then, they were irradiated (400 mJ/cm ² UVB)	Normal human epidermal keratinocytes (NHEKs)	-	- MTT (cell viability) - DCFH2-DA assay (oxidative damage) - Measure-IT High sensitivity nitrite assay (nitrite intracellular concentration). - IF, RT-PCR (expression of OGG1 and proinflammatory cytokines)	- UVB (280–320 nm) lamp VL6M - Quantum radiometer (HD9021) - Victor X Multilabel Plate Readers (PerkinElmer) - q-RT-PCR	FC-HPKs were isolated from lesions on several locations (face, trunk, scalp, lower and upper limb)	-

Table 2 (Continued)

Study location	Study population			Intervention	Control	Study duration	Test conditions (C R.T.) (% R.H.)	Outcome		Adverse effects	
	Type of study	Sample size, sex	Age, years					Health condition	Contents, daily dose		Contents, daily dose
<i>Other supplements</i>											
Pilking-ton, 2016, UK ⁴³	Clinical trial	n = 79 100% F	18–60	Healthy female volunteers with phototypes I or II	<i>Active group:</i> encapsulated n-3 PUFA supplements (70% EPA and 10% DHA). Five capsules daily.	<i>Placebo group:</i> encapsulated control lipid supplement (glyceryl tricoprylate coprate). Five capsules daily.	12 w	- Epidermal Langerhans cells number - PGs and cytokines measurement	- Fluorescence microscopy (for epidermal Langerhans cell counting on skin biopsies) - Mass spectrometer (PGs and cytokines measurement)	Skin biopsies from upper buttocks	NR
Niko-lakopoulou, 2013, UK ⁴⁴	Preclinical trial	-	-	Malignant and premalignant keratinocytes <i>Malignant cell lines:</i> - SCC-13 (facial epidermis) - SCC-25 (oral, tongue) <i>Premalignant cell lines:</i> - SVHFK (transformed epidermal) - D17, D19 and D20 (oral dysplasia)	<i>Omega-3 polyunsaturated fatty acids:</i> eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) Incubation of cell lines with 3 μM DHA and 3 or 5 μM of EPA, 16 h	Normal foreskin epidermal keratinocyte lines: - NHEK-131 - HEK-127 Normal oral keratinocyte lines: - NHOK810 - NHOK881 Non-neoplastic immortal cell lines: - OKF4 - OKF6	-	- MTT (viability) - Tritiated thymidine incorporation assay (proliferation) - DCFH2-DA and anti-8-oxo-dG assay (oxidative damage) - Apoptosis assay - EGFR, ERK1/2 and Akt pathways functioning	-	-	




Figure 1 Flow diagram for study selection process following PICAR procedure.

349 induced by UV light.²⁶ Treatment with PLE promotes the
350 expression of H2AX and p53 – triggering DNA repair machinery
351 – and slows down the progression of keratinocytes
352 through G2/M transition (favoring the G2/M checkpoint control).
353 The authors observed that PLE treatment extended
354 the duration of DNA repair phase in stem cells, enhancing
355 their ability to regenerate. Additionally, increasing the DNA
356 repair signal should decrease the number of cells undergoing
357 differentiation after cell division. Premature differentiation
358 of keratinocytes is a factor in skin aging. Nevertheless,
359 cells treated with PLE showed greater resilience vs aging,
360 maintaining a higher potential for self-renewal and proliferation
361 after treatment. Thus, this boost to DNA repair signaling
362 could prolong the renewal capacity of stem cells and diminish
363 the proportion of cells undergoing differentiation post-mitotically.²⁶

364
365 Regarding the importance to evaluate the impact of DNA
366 damage, Torricelli et al. also evaluated the preventive role
367 of PLE vs UV-induced damage.²⁷ Their preclinical trial was
368 performed in a model of reconstructed human epidermis
369 (RHE) exposed to UVB and showed that treatment with PLE

370 reduces the expression of p53 and p21, which correlated
371 with the reduction of sunburn cells formation, and prevents
372 the upregulation of proliferating proteins (EFG, Ki67)
373 and formation of CPDs.²⁷ In connection with the formation
374 of CPDs, Portillo-Esnaola et al.²⁸ analyzed the role of
375 Fernblock® (FB; the standardized hydrophilic extract from
376 the leaves of *P. leucotomos*) in preventing the formation of
377 these photoproducts in UVA-exposed murine melanocytes.
378 Results indicated that treatment with FB decreases levels
379 of both reactive oxygen species (ROS) and reactive nitrogen
380 species (RNS), thus reducing the formation of dark-CPDs.
381 Both antioxidant and scavenging properties shown by FB
382 make this compound an optimal candidate to be included
383 in sunscreens formulations.²⁸

384 Tea polyphenols extracts

385 A prospective study explored whether there is a relationship
386 between drinking black tea and the occurrence of BCC
387 and SCC. The study estimated black tea consumption in
388 1325 volunteers from 1992, 1994 and 1996 and recorded
389 all skin cancers diagnosed in these volunteers from 1997

	SB	PB	DB	AB	RP	OB
S1	+	×	+	+	+	+
S2	+	×	×	×	+	×
S3	+	×	×	×	+	+
S4	×	×	×	+	+	×
S5	+	+	+	×	+	+
S6	+	+	+	×	+	+
S7	+	+	+	×	+	+
S8	+	+	+	×	+	×
S9	+	+	+	-	+	+
S10	+	+	-	×	+	+
S11	+	+	+	×	-	-
S12	+	+	+	+	+	×

Figure 2 Summary of the reviewers' assessments for each domain of bias risk. Risk of bias. SB (selection bias); PB (performance bias); DB (detection bias); AB (attrition bias); RB (reporting bias); OB (other bias). Studies: (S1) Pellacani et al., 2023; (S2) Auriemma et al., 2015; (S3) Miura et al., 2015; (S4) Pérez-Sánchez et al., 2014; (S5) Chen et al., 2015; (S6) Chen et al., 2016; (S7) Allen et al., 2023; (S8) Freitas et al., 2015; (S9) Pasarelli et al., 2014; (S10) Pilkington et al., 2016; (S11) Donnenfeld et al., 2014; (S12) Nobile et al., 2016.

through 2007. Despite this comprehensive analysis, results showed no significant association between black tea consumption and the incidence of BCC or SCC. Therefore, black tea consumption cannot be considered as part of a preventive strategy to reduce the risk of skin cancer.²⁹

Additional polyphenol sources

Additional polyphenol sources have been investigated in various studies to explore their role in preventing UV-induced skin damage, offering promising avenues for skin protection and cancer prevention. Pérez-Sánchez et al.,³⁰ demonstrated that a combination of rosemary and citrus bioflavonoids from grapefruit (Nutroxsun®) increased cell survival, reduced intracellular ROS, prevented DNA damage, and decreased chromosomal aberrations in UVB-exposed human keratinocytes. Moreover, oral administration of this combination to human volunteers resulted in a significant increase in minimal erythema dose (MED), suggesting its potential as an oral photoprotection strategy.³⁰ Similarly, the clinical trial conducted by Nobile et al.³¹ indicated that intake of the same combination of rosemary and grapefruit

(Nutroxsun®) by volunteers with clinical signs of photoaging also lead to a decrease in skin redness and peroxidation of basal lipids and an increase in MED, as well as a decrease of wrinkle depth and an increase in skin elasticity.³¹ In another study, Maini et al.³² revealed the effectiveness of quercetin, kaempferol, and galangin in preventing UVR-induced CPD formation in artificial skin. Additionally, quercetin significantly reduced the secretion of MMP-1 and TNF- α . These findings suggest that these flavonols, traditionally considered antioxidants, could serve as a promising tool to prevent DNA damage associated with AK progression.³² Regarding skin elastosis, characterized by the accumulation of abnormal elastic fibers in the skin, Pain et al.³³ evaluated the capacity of a leaf extract from *H. virginiana* to counteract the elastin/lysyl oxidase (LOXL1) enzyme imbalance and elafin synthesis, a marker of elastotic aggregates, triggered by UV light exposure. This imbalance contributes to the accumulation of nonfunctional elastin fiber aggregates, leading to actinic aging. For that purpose, they measured LOXL1 and elafin expression in both human fibroblasts and human skin biopsies that were exposed to UVA radiation and treated with *H. virginiana* extract. The extract increased LOXL1 expression and decreased elafin synthesis, resulting in a decrease in aggregates and restoration of functional elastic fibers.³³ Phytochemicals in the diet possess chemopreventive properties that can hinder or delay the process of carcinogenesis. The lotus leaf, a traditional medicinal plant rich in numerous polyphenols, is a notable example. Lotus leaf extract, rich in phenolics and quercetin, showed strong potential in inhibiting skin carcinogenesis in murine skin JB6 P+ cells. It activated the NRF2 pathway, boosting antioxidant and detoxification enzymes like HO-1, NQO1, and UGT1A1, while also reducing DNA methylation levels. This suggests that this extract may hinder neoplastic transformation by regulating the NRF2 pathway and epigenetic processes.³⁴

Thus, the exploration of polyphenolic compounds, conducted through both clinical and preclinical studies, reveals their potential in preventing and treating various skin conditions, including AKs, BCCs, SCCs, and actinic aging. Clinical trials have demonstrated the efficacy of supplements such as *Polypodium leucotomos* extract (PLE), in improving skin health and reducing the risk of skin cancers. Preclinical experiments highlight the role of polyphenols in inhibiting DNA damage, suppressing neoplastic transformation, and protecting against UV-induced skin damage. However, not all polyphenols exhibit significant protective effects, as evidenced by the lack of association between black tea consumption and the incidence of BCC or SCC. Despite this, research into polyphenols from sources like rosemary, citrus bioflavonoids, lotus leaf extract, and *H. virginiana* extract offers promising avenues for developing effective photoprotective and chemopreventive strategies vs skin cancer and actinic aging.

Supplementation with vitamins and oligoelements

Eight studies reported the administration of vitamins and vitamin derivatives for the prevention and treatment of AKs, BCCs and SCCs, melanoma, oxidative stress, and UV-induced apoptosis. Of the 8 works, 6 corresponded to clinical studies and 2 were preclinical studies.

Regarding clinical trials, nicotinamide (NAM, a vitamin B3 derivative), folate (vitamin B9), an antioxidant complex (vitamin D + vitamin C + zinc), and vitamin D3, were administered as dietary supplements to prevent precancerous lesions (AKs) and non-melanocytic lesions (BCCs and SCCs) in a high-risk patient population including organ transplant recipients (OTR) patients, as well as melanoma. Overall, all these studies involved 8789 patients, with a mean age of 52.6 years, ranging from 30 to 91 years. Data indicated that 50.9% ($n = 4472$ female/8819) of participants were women.

Preclinical studies examined the capacity of NAM to reduce of oxidative stress associated with non-melanoma skin cancer (NMSC), and the potential role of vitamin C to inhibit UVR-induced apoptosis through modulation of DNA methylation.

Research snippets

Nicotinamide and other vitamin B derivatives

The selected studies provide valuable insights into the potential of nicotinamide (NAM) as a preventive and therapeutic agent for skin cancer. In 2015,³⁵ Chen et al. conducted a clinical trial with 386 high-risk patients with a past medical history of at least two NMSCs in the previous 5 years. Participants were randomized to receive oral NAM (500 mg) or placebo twice daily for 12 months. The evaluation by dermatologists revealed promising results, with a 20% lower rate of BCCs, a 30% lower rate of new SCCs, and a 13% lower rate of new AKs in the NAM group vs the placebo group.³⁵ In another clinical trial, Chen et al.³⁶ explored the safety and efficacy profile of NAM in preventing the appearance of BCCs and SCCs in immunosuppressed renal transplant recipients with a history of at least two NMSCs in the previous 12 months. Patients were randomized to receive oral NAM (500 mg) or placebo and skin lesions (AKs, BCCs, and SCCs) were recorded twice monthly up to 6 months by dermatologists. In this study, a reduction of BCC and SCC (35%) and of AKs (16%) were observed in the NAM vs the placebo group, yet results were not statistically significant.³⁶ In 2023, Allen et al.,³⁷ also explored the efficacy of NAM in skin cancer chemoprevention in OTR patients. A total of 158 adults who had had at least two histologically confirmed keratinocyte cancers in the past 5 years and had undergone kidney, liver, or heart or lung transplantation at least 12 months previously were enrolled. These participants randomly received oral NAM (500 mg) or matched placebo twice daily for 12 months. Evaluation by dermatologists revealed no significant differences in SCC, BCC and AK counts between the NAM and placebo group, concluding that oral NAM did not prevent the appearance of new keratinocyte cancers or AKs in immunosuppressed solid OTR.³⁷ Camillo et al. in 2022,³⁸ also analyzed the potential role of NAM as chemopreventive agent from a preclinical viewpoint. They obtained skin biopsies from 30 patients with precancerous skin lesions, dysplastic nevi, NMSCs, and/or cutaneous melanoma. From these biopsies, they isolated field cancerization human primary keratinocytes (FC-HPKs) for further study. Their findings demonstrated that NAM efficiently decreased ROS levels and the expression of oxoguanine glycosylase (OGG)1 (responsible for 8-oxoG excision) in UVB-exposed FC-HPKs, thus protecting from oxidative stress and

DNA damage induced by UVB irradiation. Furthermore, NAM prevented UVB-induced inflammation via modulation of the expression of proinflammatory cytokines (especially IL1b and TNF α). These results suggest that NAM could be a useful molecule for chemoprevention of NMSCs and the treatment of field cancerization.³⁸

All these contrasting findings about NAM highlight the complexity of the role of this compound in skin cancer prevention and underscore the need for further research to elucidate its mechanisms of action and potential therapeutic applications.

Another derivative of B vitamin is folate (vitamin B9). A prospective study performed by Donnenfeld et al.,³⁹ aimed to investigate the impact of dietary folate intake on the risk of developing skin cancer. During the study period spanning from 1994 through 2002, 5880 volunteers completed a dietary record every 2 months, detailing all foods and beverages consumed within 24-h periods. Throughout the trial, all diagnosed skin cancer lesions were meticulously documented. At the end of trial, a total of 144 incident skin cancer cases were diagnosed (20 melanoma, 18 SCC, and 106 BCC). Based on these results and on erythrocyte folate analyses – which were performed on all participants at years 2 and 5 – it was concluded that dietary folate intake was associated with an increased risk of BCC skin cancer. This association was more specifically observed in women.³⁹

Vitamin C and vitamin E

Freitas et al.,⁴⁰ conducted a study with two phases to investigate the effects of an antioxidant therapy (consisting of a complex with vitamin C, vitamin E and zinc) in the oxidative stress status of patients with a past medical history of NMSC. In phase I, plasma concentrations of several oxidative biomarkers were analyzed in 60 NMSC patients (previously treated with surgery) and 24 healthy volunteers. Results showed that NMSC patients had higher levels of all assessed oxidative markers vs healthy volunteers. In phase II, NMSC patients were randomized to receive oral antioxidant complex or placebo once daily for 2 months. In this case, evaluation of stress biomarkers after supplementation period did not reveal significant differences across groups. In conclusion, antioxidant therapy based on these vitamins did not significantly reduce levels of oxidative stress biomarkers.⁴⁰ Another *in vitro* study performed by Lin et al.⁴¹ explored the role of vitamin C on UV-induced apoptosis in cells from a human epidermoid carcinoma and p16/p21-knockout fibroblasts. As results showed, vitamin C effectively antagonized UV-induced apoptosis in skin cancer cells by promoting DNA demethylation and subsequently reactivating the activation of tumor suppressor genes p16 and p21.⁴¹

Vitamin D and oligoelements

Regarding vitamin D, Passarelli et al. in 2020,⁴² examined the effect of daily oral vitamin D or calcium supplementation on the risk of developing BCC or invasive cutaneous SCC. They enrolled a total of 2259 patients diagnosed with a colorectal adenoma in this clinical trial. Participants were randomized to receive 1 of these 4 groups: (1) 1000 IU/day of vitamin D3; (2) 1200 mg/day of calcium carbonate; (3) both vitamin D3 and calcium carbonate; (4) placebo. Supplemen-

tation period was 3 or 5 years, and during that period the incidence of BCC or SCC was reported. Results indicated that while BCC incidence was not related to the supplementation administered, calcium carbonate supplementation – alone or in combination with vitamin D – seemed to reduce the incidence of SCC, suggesting the preventive role of calcium in the development of SCC.⁴²

Therefore, the investigation into vitamin supplementation for the prevention and treatment of various skin conditions presents diverse findings and implications. Clinical trials have explored the potential benefits of NAM, folate (vitamin B9), antioxidant complexes, and vitamin D3 in reducing the risk of precancerous lesions, NMSCs, and melanocytic lesions. Conflicting results from these trials highlight the complexity of the role of such vitamins in skin cancer prevention, particularly evident in the case of NAM, where its efficacy varies across different studies. Preclinical studies further elucidate the mechanisms underlying the protective effects of these vitamins, such as NAM's ability to reduce oxidative stress and inflammation and folate's association with an increased risk of skin cancer, especially in women. Additionally, vitamin C shows promise in modulating UV-induced apoptosis and promoting DNA demethylation in skin cancer cells. The role of vitamin D supplementation, particularly calcium carbonate, appears to have a preventive effect on the incidence of invasive cutaneous SCC. Overall, these findings underscore the importance of continued research to better understand the mechanisms of action and optimize the therapeutic potential of vitamin supplementation in skin cancer prevention and treatment.

Supplementation with other supplements

Two studies reported on the use of different compounds for inhibition of growth and development of SCCs, and the prevention of UV-induced damage to immune system. One of these two studies is a clinical trial and the other a preclinical trial.

Regarding clinical trial, omega-3 polyunsaturated fatty acids (Ω -3 PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were evaluated as dietary supplements for the prevention of UVR-induced damage to immune system. This study involved 79 women, with a mean age of 40.6 years, ranging from 21 to 60 years old.

Preclinical trial examined the capacity of EPA and DHA to inhibit the growth of cells obtained from human oral and facial SCC.⁴³

Research snippets

Ω -3 polyunsaturated fatty acids (PUFAs): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). A clinical trial conducted by Pilkington et al.⁴³ evaluated the protective role EPA and DHA on cell-mediated immunity – the suppression of which is one of the effects of UVR exposure – through the analysis of the number of Langerhans cells (LC) and immunomodulatory mediators. For that, 79 healthy volunteers randomly received 5 capsules *per day* containing 70% EPA and 10% DHA or placebo, for 12 weeks. Moreover, specific areas of their buttocks were exposed to UVR before and after supplementation. Analysis of collected samples did not find any differences in the number of LC and immunomodulatory

mediators between EPA and placebo groups after UVR exposure. Therefore, there was no evidence that EPA reduces UVR suppression of skin immunity by changes in the number of epidermal LC or immunomodulatory mediators.⁴³ Within this context, Nikolakopoulou et al.⁴⁴ conducted laboratory research to assess how n-3 PUFAs affect the proliferation of premalignant and malignant keratinocytes from facial and oral human SCCs. Their findings indicated that DHA and particularly EPA specifically inhibited the proliferation of these keratinocytes by activating the ERK1/2 pathway and inducing both apoptosis and cell cycle arrest.⁴⁴

Therefore, alternative supplements like omega-3 PUFAs show potential in reducing UVR-induced damage and preventing SCC growth. While clinical trials yield mixed results, preclinical studies indicate promising effects of Ω -3 PUFAs in inhibiting the growth of malignant keratinocytes.

Conclusions

Finally, we can conclude that the reviewed studies support the potential efficacy profile of polyphenols in the prevention of cancerous lesions, particularly due to their protective effects vs DNA damage and UV-induced harm. However, of note, the limitations of the reviewed studies, including small sample sizes, variability in study designs, and the possible impact of uncontrolled variables. Moreover, it is essential to emphasize that integral photoprotection, which includes the use of topical, oral photoprotectors and the adoption of photoprotective habits, remains the most recommended strategy for skin cancer prevention. In this context, further clinical studies should aim to investigate the impact of dietary supplements, particularly in high-risk populations and explore different combinations of ingredients with varied mechanisms of action to optimize therapeutic applications.

Ethical approval

The study protocol was registered on PROSPERO (CRD42023485985).

Conflicts of interest

G.P received grants to institution from AbbVie, Almirall, Galderma, Leo, Lilly, Novartis, Pierre Fabre and Pfizer. K.P received grants from Sanofi, Novartis, AbbVie and Almirall. Consulting fees from Sanofi, honoraria for lectures and educational events from Lilly, Sanofi and Sun Pharma, participation in advisory boards AbbVie and Almirall. Leo Pharma, Lilly, Janssen, Sanofi, Pierre Fabre, Sun Pharma, Biogen, Galderma and Philogen. P.C-P has acted as an advisory board member for AbbVie, Almirall, Cantabria, Galderma, Janssen, LEO Pharma, Novartis, Boehringer Ingelheim, Molteni and Sanofi, has received grants for talks from Almirall, AbbVie, Novartis, LEO Pharma, Sanofi, Novartis, and has acted as an investigator for Clinuvel, Mitsubishi, Novartis, Sanofi, Galderma, LEO Pharma, Amgen, Biogen, Pierre Fabre, Regeneron, and SI Health. M.V.deG has served as an investigator and speaker for Cantabria labs, La Roche-Posay, Beiersdorf, ISDIN, Pierre Fabre, Rilastil. Y.G received

699 support as an advisor, researcher, or speaker from Galderma,
700 Almirall, Cantabria Labs, AbbVie, Lilly, Sanofi, UCB, Isdin,
701 PfizerRoche, and Roche-Posay. S.G has a consultant role for
702 Cantabria Labs.

703 The remaining authors declared no conflicts of interest
704 whatsoever.

705 Appendix A. Supplementary data

706 Supplementary data associated with this article
707 can be found in the online version available at
708 <https://doi.org/10.1016/j.ad.2024.12.019>.

709 References

710 1. George CD, Lee T, Hollestein LM, Asgari MM, Nijsten T.
711 Global epidemiology of actinic keratosis in the general popu-
712 lation: a systematic review and meta-analysis. *Br J Dermatol*.
713 2024;190:465–76, <http://dx.doi.org/10.1093/bjd/ljad371>.
714 2. Papageorgiou C, Lallas A, Manoli SM, Longo C, Lai M,
715 Liopyris K, et al. Evaluation of dermatoscopic criteria for
716 early detection of squamous cell carcinoma arising on
717 an actinic keratosis. *J Am Acad Dermatol*. 2022;86:791–6,
718 <http://dx.doi.org/10.1016/j.jaad.2021.03.111>.
719 3. Figueras Nart I, Cerio R, Dirschka T, Dréno B, Lear JT, Pellacani
720 G, et al. Defining the actinic keratosis field: a literature review
721 and discussion. *J Eur Acad Dermatol Venereol*. 2018;32:544–63,
722 <http://dx.doi.org/10.1111/JDV.14652>.
723 4. Ferrándiz-Pulido C, Lera-Imbuluzqueta M, Ferrándiz C, Plazas-
724 Fernandez MJ. Prevalence of actinic keratosis in different
725 regions of Spain: the EPIQA study. *Actas Dermosifiliogr*.
726 2018;109:83–6, <http://dx.doi.org/10.1016/J.AD.2017.05.014>.
727 5. Buendía-Eisman A, Arias-Santiago S, Molina-Leyva A,
728 Gilaberte Y, Fernández-Crehuet P, Husein-ElAhmed H,
729 et al. Outpatient dermatological diagnoses in Spain:
730 results from the National DIADERM Random Sam-
731 pling Project. *Actas Dermosifiliogr*. 2018;109:416–23,
732 <http://dx.doi.org/10.1016/J.AD.2018.02.003>.
733 6. Fernandez Figueras MT. From actinic keratosis to squamous
734 cell carcinoma: pathophysiology revisited. *J Eur Acad Dermatol*
735 *Venereol*. 2017;31:5–7, <http://dx.doi.org/10.1111/JDV.14151>.
736 7. Nindl I, Dang C, Forschner T, Kuban RJ, Meyer T, Sterry W, et al.
737 Identification of differentially expressed genes in cutaneous
738 squamous cell carcinoma by microarray expression profiling. *Mol*
739 *Cancer*. 2006;5:30, <http://dx.doi.org/10.1186/1476-4598-5-30>.
740 8. Stockfleth E. The importance of treating the field in actinic
741 keratosis. *J Eur Acad Dermatol Venereol*. 2017;31:8–11,
742 <http://dx.doi.org/10.1111/jdv.14092>.
743 9. Ruini C, Witkowski AM, Cesinaro A, Teixeira De Car-
744 valho N, Pellacani G. From actinic keratosis to squa-
745 mous cell carcinoma: evidence of morphologic and biologic
746 progression. *J Am Acad Dermatol*. 2015;72:58–10,
747 <http://dx.doi.org/10.1016/j.jaad.2014.02.046>.
748 10. Zakria D, Brownstone N, Berman B, Ceilley R, Cronin TA, Del
749 Rosso JQ, et al. Incorporating a prognostic gene expression
750 profile test into the management of cutaneous squamous cell
751 carcinoma: an expert consensus panel report. *J Drugs Dermatol*.
752 2024;23:54–60, <http://dx.doi.org/10.36849/JDD.7691>.
753 11. Slaughter D, Southwick H, Smejkal W. Field canceriza-
754 tion in oral stratified squamous epithelium: clinical
755 implications of multicentric origin. *Cancer*. 1953;6:963–8,
756 [http://dx.doi.org/10.1002/1097-0142\(195309\)6:5<963::aid-
758 cncr2820060515>3.0.co;2-q](http://dx.doi.org/10.1002/1097-0142(195309)6:5<963::aid-
757 cncr2820060515>3.0.co;2-q).
759 12. Braathen LR, Morton CA, Basset-Seguín N, Bissonnette R,
Gerritsen MJP, Gilaberte Y, et al. Photodynamic therapy

760 for skin field cancerization: an international consensus.
761 International Society for Photodynamic Therapy in Derma-
762 tology. *J Eur Acad Dermatol Venereol*. 2012;26:1063–6,
763 <http://dx.doi.org/10.1111/J.1468-3083.2011.04432.X>.
764 13. Malvey J. A new vision of actinic keratosis beyond visible clini-
765 cal lesions. *J Eur Acad Dermatol Venereol*. 2015;29 Suppl. 1:3–8,
766 <http://dx.doi.org/10.1111/JDV.12833>.
767 14. Arcuri D, Ramchatesingh B, Lagacé F, Iannattone L,
768 Netchiporouk E, Lefrançois P, et al. Pharmacologi-
769 cal agents used in the prevention and treatment of
770 actinic keratosis: a review. *Int J Mol Sci*. 2023;24,
771 <http://dx.doi.org/10.3390/IJMS24054989>.
772 15. Puig S, Granger C, Garre A, Trullàs C, Sanmartín O, Argenziano
773 G. Review of clinical evidence over 10 years on prevention
774 and treatment of a film-forming medical device contain-
775 ing photolyase in the management of field cancerization in
776 actinic keratosis. *Dermatol Ther (Heidelb)*. 2019;9:259–70,
777 <http://dx.doi.org/10.1007/S13555-019-0294-1>.
778 16. Bakirtzi K, Papadimitriou I, Vakirlis E, Lallas A, Sotiriou E.
779 Photodynamic therapy for field cancerization in the skin:
780 where do we stand? *Dermatol Pract Concept*. 2023;13,
781 <http://dx.doi.org/10.5826/DPC.1304A291>.
782 17. Moscarella E, Di Brizzi EV, Casari A, De Giorgi V, Di Meo N,
783 Fargnoli MC, et al. Italian expert consensus paper on the
784 management of patients with actinic keratoses. *Dermatol Ther*.
785 2020;33:e13992, <http://dx.doi.org/10.1111/DTH.13992>.
786 18. Piquero-Casals J, Morgado-Carrasco D, Gilaberte Y, Del
787 Rio R, Macaya-Pascual A, Granger C, et al. Manage-
788 ment pearls on the treatment of actinic keratoses and
789 field cancerization. *Dermatol Ther (Heidelb)*. 2020;10:903,
790 <http://dx.doi.org/10.1007/S13555-020-00425-4>.
791 19. Chetty P, Choi F, Mitchell T. Primary care review of
792 actinic keratosis and its therapeutic options: a global
793 perspective. *Dermatol Ther (Heidelb)*. 2015;5:19,
794 <http://dx.doi.org/10.1007/S13555-015-0070-9>.
795 20. Lucena SR, Salazar N, Gracia-Cazaña T, Zamarrón A,
796 González S, Juarranz Á, et al. Combined treatments
797 with photodynamic therapy for non-melanoma skin cancer.
798 *Int J Mol Sci*. 2015;16:25912, <http://dx.doi.org/10.3390/IJMS161025912>.
799 21. Pellacani G, Peris K, Ciardo S, Pezzini C, Tambone S,
800 Farnetani F, et al. The combination of oral and topi-
801 cal photoprotection with a standardized *Polypodium leu-*
802 *cotomos* extract is beneficial against actinic keratosis.
803 *Photodermatol Photoimmunol Photomed*. 2023;39:384–91,
804 <http://dx.doi.org/10.1111/phpp.12870>.
805 22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred
806 reporting items for systematic reviews and meta-analyses:
807 the PRISMA statement. *Int J Surg*. 2010;8:336–41,
808 <http://dx.doi.org/10.1016/J.IJSU.2010.02.007>.
809 23. Wang Q, Liao J, Lapata M, Macleod M. Risk of bias
810 assessment in preclinical literature using natural lan-
811 guage processing. *Res Synth Methods*. 2022;13:368–80,
812 <http://dx.doi.org/10.1002/JRSM.1533>.
813 24. Sun Q, Wu J, Qian G, Cheng H. Effectiveness of
814 dietary supplement for skin moisturizing in healthy
815 adults: a systematic review and meta-analysis of ran-
816 domized controlled trials. *Front Nutr*. 2022;9:895192,
817 <http://dx.doi.org/10.3389/FNUT.2022.895192/FULL>.
818 25. Auriemma M, Di Nicola M, Gonzalez S, Piaserico S, Capo A, Ame-
819 rio P. *Polypodium leucotomos* supplementation in the treatment
820 of scalp actinic keratosis. *Dermatol Surg*. 2015;41:898–902,
821 <http://dx.doi.org/10.1097/DSS.0000000000000425>.
822 26. Gandarillas A, Guerrero A, Delgado-Rubin A, González S,
823 Rodríguez-Luna A, San Juan L. Extract from the leaves of *Poly-*
824 *podium leucotomos* stimulates DNA repair signals γ H2AX and
825 P53 to prolong the keratinocyte DNA repair phase of the cell
826 cycle. *J Cosmet Sci*. 2023;74:173–87. 827

- 828 27. Torricelli P, Fini M, Fanti PA, Dika E, Milani M. Protective
829 effects of *Polypodium leucotomos* extract against UVB-induced
830 damage in a model of reconstructed human epidermis.
831 Photodermatol Photoimmunol Photomed. 2017;33:156–63,
832 <http://dx.doi.org/10.1111/phpp.12297>.
- 833 28. Portillo-Esnaola M, Rodríguez-Luna A, Nicolás-Morala J,
834 Gallego-Rentero M, Villalba M, Juarranz Á, et al. Forma-
835 tion of cyclobutane pyrimidine dimers after UVA
836 exposure (Dark-CPDs) is inhibited by a hydrophilic
837 extract of *Polypodium leucotomos*. Antioxidants. 2021;10,
838 <http://dx.doi.org/10.3390/antiox10121961>.
- 839 29. Miura K, Hughes MCB, Arovah NI, Van Der Pols JC, Green
840 AC. Black tea consumption and risk of skin cancer: an
841 11-year prospective study. Nutr Cancer. 2015;67:1049–55,
842 <http://dx.doi.org/10.1080/01635581.2015.1073759>.
- 843 30. Pérez-Sánchez A, Barrajón-Catalán E, Caturla N,
844 Castillo J, Benavente-García O, Alcaraz M, et al. Pro-
845 tective effects of citrus and rosemary extracts on
846 UV-induced damage in skin cell model and human
847 volunteers. J Photochem Photobiol B. 2014;136:12–8,
848 <http://dx.doi.org/10.1016/j.jphotobiol.2014.04.007>.
- 849 31. Nobile V, Michelotti A, Cestone E, Caturla N, Castillo J,
850 Benavente-García O, et al. Skin photoprotective and antiageing
851 effects of a combination of rosemary (*Rosmarinus officinalis*)
852 and grapefruit (*Citrus paradisi*) polyphenols. Food Nutr Res.
853 2016;1, <http://dx.doi.org/10.3402/fnr.v60.31871>.
- 854 32. Maini S, Fahlman BM, Krol ES. Flavonols protect against UV
855 radiation-induced thymine dimer formation in an artificial skin
856 mimic. J Pharm Pharm Sci. 2015;18:600–15. Available from:
857 www.cspCanada.org [accessed 15.03.24].
- 858 33. Pain S, Berthélémy N, Naudin C, Degraive V, André-Frei V. Under-
859 standing solar skin elastosis – cause and treatment. J Cosmet
860 Sci. 2018;69:175–85.
- 861 34. Tung YC, Sung PH, Chen PC, Wang HC, Lee JH, Su ZY. Chemo-
862 ^{Q4}prevention of lotus leaf ethanolic extract through epigenetic
863 activation of the NRF2-mediated pathway in murine skin JB6 P⁺
864 cell neoplastic transformation. J Tradit Complement Med. 2023,
865 <http://dx.doi.org/10.1016/j.jtcm.2023.02.002>.
- 866 35. Chen AC, Martin AJ, Choy B, Fernández-Peñas P,
867 Dalziel RA, McKenzie CA, et al. A phase 3 ran-
868 domized trial of nicotinamide for skin-cancer
869 chemoprevention. N Engl J Med. 2015;373:1618–26,
870 <http://dx.doi.org/10.1056/nejmoa1506197>.
- 871 36. Chen AC, Martin AJ, Dalziel RA, McKenzie CA, Lowe
PM, Eris JM, et al. A phase II randomized controlled
trial of nicotinamide for skin cancer chemoprevention in
renal transplant recipients. Br J Dermatol. 2016;175:1073–5,
<http://dx.doi.org/10.1111/BJD.14662>.
37. Allen NC, Martin AJ, Snaird VA, Eggins R, Chong AH, Fernández-
Peñas P, et al. Nicotinamide for skin-cancer chemoprevention
in transplant recipients. N Engl J Med. 2023;388:804–12,
<http://dx.doi.org/10.1056/NEJMoa2203086>.
38. Camillo L, Gironi LC, Zavattaro E, Esposto E, Savoia P.
Nicotinamide attenuates UV-induced stress damage in human
primary keratinocytes from cancerization fields. J Invest Derma-
tol. 2022;142, <http://dx.doi.org/10.1016/J.JID.2021.10.012>,
1466–1477.e1.
39. Donnenfeld M, Deschasaux M, Latino-Martel P, Diallo
A, Galan P, Hercberg S, et al. Prospective association
between dietary folate intake and skin cancer risk: results
from the Supplémentation en Vitamines et Minéraux
Antioxydants cohort. Am J Clin Nutr. 2015;102:471–8,
<http://dx.doi.org/10.3945/AJCN.115.109041>.
40. Silva De Almendra Freitas BDJE, Lloret GR, Visacri MB, Tuan BT,
Amaral LS, Baldini D, et al. High 15-F2t-isoprostane levels in
patients with a previous history of nonmelanoma skin cancer:
the effects of supplementary antioxidant therapy. Biomed Res
Int. 2015;2015, <http://dx.doi.org/10.1155/2015/963569>.
41. Lin JR, Qin HH, Wu WY, He SJ, Xu JH. Vitamin C protects
against UV irradiation-induced apoptosis through reactivat-
ing silenced tumor suppressor genes p21 and p16 in a
Tet-dependent DNA demethylation manner in human skin
cancer cells. Cancer Biother Radiopharm. 2014;29:257–64,
<http://dx.doi.org/10.1089/CBR.2014.1647>.
42. Passarelli MN, Karagas MR, Mott LA, Rees JR, Barry EL,
Baron JA. Risk of keratinocyte carcinomas with vitamin D
and calcium supplementation: a secondary analysis of a
randomized clinical trial. Am J Clin Nutr. 2020;112:1532,
<http://dx.doi.org/10.1093/AJCN/NQAA267>.
43. Pilkington SM, Gibbs NK, Costello P, Bennett SP, Massey KA,
Friedmann PS, et al. Effect of oral eicosapentaenoic acid on epi-
dermal Langerhans cell numbers and PGD2 production in UVR-
exposed human skin: a randomised controlled study. Exp Der-
matol. 2016;25:962–8, <http://dx.doi.org/10.1111/EXD.13177>.
44. Nikolakopoulou Z, Nteliopoulos G, Michael-Titus AT, Parkin-
son EK. Omega-3 polyunsaturated fatty acids selectively
inhibit growth in neoplastic oral keratinocytes by differ-
entially activating ERK1/2. Carcinogenesis. 2013;34:2716–25,
<http://dx.doi.org/10.1093/carcin/bgt257>.